Quick Answer
Lineage Cell Therapeutics, Inc. reported Revenue (ASC 606) of $14.56 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $14.56M | +53.2% |
| 2024 | $9.50M | +6.2% |
| 2023 | $8.95M | -39.2% |
| 2022 | $14.70M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.68M | -2.6% | +33.1% |
| June 30, 2025 | $2.77M | +96.4% | +84.1% |
| March 31, 2025 | $1.50M | +4.0% | -60.3% |
| September 30, 2024 | $3.78M | +203.3% | +168.4% |
| June 30, 2024 | $1.41M | -56.3% | -2.5% |
| March 31, 2024 | $1.44M | -39.5% | +15.9% |
| September 30, 2023 | $1.25M | -58.4% | -61.4% |
| June 30, 2023 | $3.23M | — | +35.2% |
- Lineage Cell Therapeutics, Inc. showed an increase of +53.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2022–2025 period, Lineage Cell Therapeutics, Inc.’s revenue (asc 606) has declined by 1.0% (from $14.70 million to $14.56 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: